Setting new standards in information exchange for the pharmaceutical and biotech industry
Alternative Model to Transform a Funding Gap in Rare Disease Clinical Research: Neuroendocrine Cancer in the Pancreas
April 6, 2016
Frustrated that a promising therapy for a rare cancer was sitting in a freezer due to the lack of a relatively modest amount of funding, author Alexander Masters helped lead a campaign to crowd-fund a clinical trial: the result, iCancer.org.uk. The money required was indeed raised – by one wealthy individual primarily, in return for being in the trial.
At DPharm Europe, Pfizer’s Craig Lipset interviewed on stage Alexander Masters to share his innovative story. We are delighted to share the journey and the latest updates on PharmaTalk Radio. In this disruptive discussion, we address:
- The remarkable story of the formation of iCancer.org.uk and the Oncolytic Virus Fund
- An alternative way to make clinical trials more accessible
- Ethical and moral issues
- A possible disruptive and sustainable business model for other neglected medicines
Listen to the show here.
The next DPharm: Disruptive Innovations to Advance Clinical Trials event takes place September 20-21 in Boston. The DPharm Europe event is scheduled for early February 8-9, 2017 in London. For more information about these events or our Immuno-Oncology events (IO 360° and Rational Combinations 360°), visit www.theconferenceforum.org.
Craig Lipset, MBA, Head of Clinical Innovation, R&D, Pfizer
Alexander Masters, Author, Campaigner and Co-Founder, iCancer.org.uk
Valerie Bowling, Executive Director, Conference Forum & Pharma Talk Radio
Telegraph Article Referenced by Craig During the Program: It’s time to sell tickets for places on life-saving medical trials